Shanghai RAAS(002252)2022-04-29 16:00Financial Performance - The company's operating revenue for Q1 2022 was RMB 1,685,498,423.72, representing a 97.32% increase compared to RMB 854,205,643.53 in the same period last year[4]. - Net profit attributable to shareholders was RMB 548,033,363.89, up 28.63% from RMB 426,048,265.01 year-on-year[4]. - The net cash flow from operating activities increased by 44.25% to RMB 415,302,906.87, compared to RMB 287,898,726.08 in the previous year[4]. - The basic and diluted earnings per share were both RMB 0.081, reflecting a 28.57% increase from RMB 0.063 in the same period last year[4]. - The net profit margin improved to approximately 32.4% in Q1 2022, compared to 49.7% in the same period last year, indicating a shift in profitability dynamics[17]. - The total profit for Q1 2022 was CNY 645,212,896.49, an increase of 35.6% from CNY 475,740,853.68 in Q1 2021[39]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 27,698,268,156.38, a 1.70% increase from RMB 27,236,582,048.82 at the end of the previous year[4]. - The total assets of Shanghai RAAS Blood Products Co., Ltd. reached approximately CNY 27.70 billion as of March 31, 2022, an increase from CNY 27.24 billion at the beginning of the year, reflecting a growth of about 1.68%[12][13]. - The company's total liabilities decreased slightly to ¥1,314,844,595.07 from ¥1,332,415,396.48, showing a reduction of approximately 1.3%[15]. - The company's accounts payable decreased to CNY 933.69 million from CNY 966.05 million, a reduction of approximately 3.35%[13]. Cash Flow - The company's cash and cash equivalents amounted to CNY 3.02 billion, up from CNY 2.75 billion at the beginning of the year, representing an increase of approximately 10.05%[12]. - The cash flow from operating activities netted CNY 415,302,906.87, compared to CNY 287,898,726.08 in the previous year, indicating a rise of 44.3%[42]. - The company reported a net cash outflow from investing activities of ¥66,788,256.17, an improvement from a net outflow of ¥85,298,102.62 in the same period last year[26]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 132,064, with the largest shareholder, GRIFOLS, S.A., holding 26.20% of the shares[10]. - The total equity attributable to shareholders increased to ¥26,383,748,240.39 from ¥25,902,445,517.58, reflecting a growth of about 1.8%[36]. Research and Development - Research and development expenses rose by 62.59% to RMB 34,400,140.41, driven by increased R&D activities[9]. - The company is actively engaged in research and development of new products and technologies to enhance its market position[11]. - The company reported R&D expenses of ¥34,400,140.41 for Q1 2022, an increase from ¥21,157,204.66 in the same period last year, representing a growth of approximately 62.3%[38]. Investment Income - The company reported a decrease in investment income by 30.15% to RMB 110,489,501.71, attributed to reduced investment income from associated companies[9]. - The company's investment income decreased by 30.15% to CNY 110,489,501.71, primarily due to reduced investment returns from associated companies[31]. Future Outlook - Future outlook includes plans for market expansion and potential mergers and acquisitions to drive growth[11].